Future breakthroughs will likely depend on integrating these strategies to contextually amplify beneficial IFN responses while constraining pathological signaling, thereby transforming IFN biology into a controllable therapeutic axis across infection, autoimmunity, and cancer. The gene discussed is IFNA1; the disease is cancer.